Chronic kidney disease (CKD) is both more common and has a higher morbidity in the United States (US) Black population compared to other racial/ethnic groups. Close to 20% of US Black individuals have CKD and they are 3.8 times more likely to progress to end-stage kidney disease (ESKD) than US White individuals with CKD.1 In 2010, a genetic driver of this ethnic disparity was uncovered in the apolipoprotein L1 (APOL1) gene. Two variants common in individuals of African descent, termed “G1” and “G2,” were found to vastly increase risk of certain forms of kidney disease when present in homozygosity (G1/G1 or G2/G2) or compound heterozygosity (G1/G2).